Corporate Profile

Founded in July 2011, CURE Pharmaceutical® is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm®), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.

Cure Pharmaceutical Corporation is a wholly-owned subsidiary of Cure Pharmaceutical Holding Corp, a public company. 

CURE PHARMACEUTICAL
1620 Beacon Place
Oxnard, CA 93033
Phone: (805) 824-0410
Fax: (805) 487-7163

Liviakis Financial Communications, Inc.
655 Redwood Hwy., Suite 395
Mill Valley, CA 94942
(415) 389-04670
www.liviakis.com

Stock Performance

Market Data copyright © 2018 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

Management Team

  • Robert Davidson - Chief Executive Officer

  • Jessica Rousset - Chief Operating Officer

  • Michael Redard - Chief Financial Officer

  • Mark Udell - Chief Accounting Officer

  • Steven Ruhl - VP of Manufacturing

  • Vered Gigi, PhD - VP of Strategy and Business Development

  • Gary Speier, MS, JD, MBA - Intellectual Property Counsel

  • Paul T. Sudhakar, MS, MBA - Regulatory Counsel

Board of Directors

  • William Yuan - Chairman of the Board

  • Lauren Chung, Ph.D - Director

  • Robert Davidson - Chief Executive Officer

  • Anya Goldin - Director

  • Joshua Held - Director

  • Ruben Jose King-Shaw Jr. - Director

  • Gene Salkind, MD - Director

Other Information

Full Time Employees: 15

CUSIP Number: 23127P104

Fiscal Year Ends: 12/31

Shares Outstanding: 23,336,673